JP5828903B2 - 新規特異的ｈｃｖ ｎｓ３プロテアーゼ阻害剤 - Google Patents

新規特異的ｈｃｖ ｎｓ３プロテアーゼ阻害剤 Download PDF

Info

Publication number
JP5828903B2
JP5828903B2 JP2013537733A JP2013537733A JP5828903B2 JP 5828903 B2 JP5828903 B2 JP 5828903B2 JP 2013537733 A JP2013537733 A JP 2013537733A JP 2013537733 A JP2013537733 A JP 2013537733A JP 5828903 B2 JP5828903 B2 JP 5828903B2
Authority
JP
Japan
Prior art keywords
compound
agent
hcv
drug
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013537733A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013542955A (ja
JP2013542955A5 (https=
Inventor
ジェローム クルカンベック
ジェローム クルカンベック
フィリップ アルフォン
フィリップ アルフォン
ムーラ ブジディ
ムーラ ブジディ
スティーブン ジェー． コーツ
スティーブン ジェー． コーツ
リチャード アンソニー ウィテカー
リチャード アンソニー ウィテカー
Original Assignee
アールエフエス ファーマ，エルエルシー
アールエフエス ファーマ，エルエルシー
ジェノサイエンス ファーマ
ジェノサイエンス ファーマ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アールエフエス ファーマ，エルエルシー, アールエフエス ファーマ，エルエルシー, ジェノサイエンス ファーマ, ジェノサイエンス ファーマ filed Critical アールエフエス ファーマ，エルエルシー
Publication of JP2013542955A publication Critical patent/JP2013542955A/ja
Publication of JP2013542955A5 publication Critical patent/JP2013542955A5/ja
Application granted granted Critical
Publication of JP5828903B2 publication Critical patent/JP5828903B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2013537733A 2010-11-01 2011-10-28 新規特異的ｈｃｖ ｎｓ３プロテアーゼ阻害剤 Expired - Fee Related JP5828903B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40898910P 2010-11-01 2010-11-01
US61/408,989 2010-11-01
PCT/US2011/058404 WO2012061248A2 (en) 2010-11-01 2011-10-28 Novel specific hcv ns3 protease inhibitors

Publications (3)

Publication Number Publication Date
JP2013542955A JP2013542955A (ja) 2013-11-28
JP2013542955A5 JP2013542955A5 (https=) 2015-02-12
JP5828903B2 true JP5828903B2 (ja) 2015-12-09

Family

ID=46025037

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013537733A Expired - Fee Related JP5828903B2 (ja) 2010-11-01 2011-10-28 新規特異的ｈｃｖ ｎｓ３プロテアーゼ阻害剤

Country Status (10)

Country Link
US (1) US8729014B2 (https=)
EP (1) EP2635570B1 (https=)
JP (1) JP5828903B2 (https=)
CN (1) CN103328466B (https=)
AU (1) AU2011323658A1 (https=)
BR (1) BR112013010836A2 (https=)
CA (1) CA2815855C (https=)
IL (1) IL225908A0 (https=)
MX (1) MX2013004906A (https=)
WO (1) WO2012061248A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013529627A (ja) 2010-06-24 2013-07-22 パンメド リミテッド ヒドロキシクロロキンまたはヒドロキシクロロキンおよび抗ウイルス剤の組合せを使用するｃ型肝炎ウイルス関連疾患の処置
MX2013004906A (es) 2010-11-01 2013-12-06 Genoscience Pharma Nuevos inhibidores especificos de la proteasa ns3 de hcv.
WO2012176149A1 (en) 2011-06-23 2012-12-27 Panmed Ltd. Treatment of hepatitis c virus
US9040479B2 (en) 2012-01-12 2015-05-26 Cocrystal Pharma, Inc. HCV NS3 protease inhibitors
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
WO2014145095A1 (en) 2013-03-15 2014-09-18 Gilead Sciences, Inc. Macrocyclic and bicyclic inhibitors of hepatitis c virus
BR112016023833A2 (pt) * 2014-04-15 2017-10-10 Cocrystal Pharma Inc compostos, composições, métodos e uso para tratar ou prevenir infecções por vírus da hepatite c
CN105315261A (zh) * 2014-08-04 2016-02-10 正大天晴药业集团股份有限公司 Hcv ns3蛋白酶抑制剂的钠盐

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000536A1 (en) 1993-06-22 1995-01-05 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds
KR100509388B1 (ko) 1996-10-18 2005-08-23 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 간염 ｃ 바이러스 ｎｓ３ 프로테아제의 저해제
US6767991B1 (en) 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
ES2240446T3 (es) 2000-04-03 2005-10-16 Vertex Pharma Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c.
AU2002331064B2 (en) 2001-08-10 2007-08-23 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
WO2004032827A2 (en) 2002-05-20 2004-04-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
BRPI0412502A (pt) 2003-07-10 2006-09-19 Achillion Pharmaceuticals Inc derivados de ariltiouréia substituìda úteis como inibidores de replicação viral
JP4902361B2 (ja) 2004-01-30 2012-03-21 メディヴィル・アクチエボラーグ Ｈｃｖｎｓ−３セリンプロテアーゼインヒビター
ES2328596T3 (es) 2004-05-20 2009-11-16 Schering Corporation Prolinas sustituidas como inhibidores de la serina proteasa del virus ns3 de la hepatitis c.
US7323447B2 (en) * 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2006111906A2 (en) 2005-04-19 2006-10-26 Philips Intellectual Property & Standards Gmbh Illumination system comprising a red-emitting ceramic luminescence converter
TWI387603B (zh) 2005-07-20 2013-03-01 Merck Sharp & Dohme Ｈｃｖ ｎｓ３蛋白酶抑制劑
BRPI0614205A2 (pt) 2005-08-01 2016-11-22 Merck & Co Inc composto, composição farmacêutica, e, uso de composto
EP2029153A2 (en) 2006-01-27 2009-03-04 Phenomix Corporation Hepatitis c serine protease inhibitors and uses therefor
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
CN101495457A (zh) * 2006-07-05 2009-07-29 因特蒙公司 C型肝炎病毒复制的新颖抑制剂
US7635683B2 (en) 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
CN101553170B (zh) 2006-11-24 2011-11-09 株式会社岛津制作所 X射线透视摄影装置
WO2008134397A1 (en) 2007-04-26 2008-11-06 Enanta Pharmaceuticals, Inc. Aza-tripeptide hepatitis c serine protease inhibitors
MX2010006210A (es) 2007-12-05 2010-08-10 Enanta Pharm Inc Inhibidores de serina proteasa de hcv de tripeptido fluorado.
US8293705B2 (en) * 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
CA2710144A1 (en) 2007-12-21 2009-07-02 Avila Therapeutics, Inc. Hcv protease inhibitors and uses thereof
EA201071034A1 (ru) 2008-04-15 2011-06-30 Интермьюн, Инк. Новые макроциклические ингибиторы репликаций вируса гепатита с
AU2011209051B2 (en) * 2010-01-27 2015-01-15 AB Pharma Ltd. Polyheterocyclic compounds highly potent as HCV inhibitors
MX2013004906A (es) 2010-11-01 2013-12-06 Genoscience Pharma Nuevos inhibidores especificos de la proteasa ns3 de hcv.

Also Published As

Publication number Publication date
EP2635570A2 (en) 2013-09-11
US8729014B2 (en) 2014-05-20
EP2635570A4 (en) 2014-04-16
CN103328466A (zh) 2013-09-25
US20120129765A1 (en) 2012-05-24
AU2011323658A1 (en) 2013-05-23
WO2012061248A2 (en) 2012-05-10
BR112013010836A2 (pt) 2019-09-24
CN103328466B (zh) 2016-08-03
MX2013004906A (es) 2013-12-06
WO2012061248A3 (en) 2012-08-02
EP2635570B1 (en) 2017-12-13
JP2013542955A (ja) 2013-11-28
CA2815855C (en) 2016-02-02
CA2815855A1 (en) 2012-05-10
WO2012061248A8 (en) 2013-08-01
IL225908A0 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
US11859014B2 (en) Peptidomimetics for the treatment of Norovirus infection
US9040479B2 (en) HCV NS3 protease inhibitors
US9932326B2 (en) Potent and selective inhibitors of hepatitis C virus
EP3980400B1 (en) Peptidomimetics for the treatment of coronavirus and picornavirus infections
JP5828903B2 (ja) 新規特異的ｈｃｖ ｎｓ３プロテアーゼ阻害剤
US20140212382A1 (en) Purine monophosphate prodrugs for treatment of viral infections
US20170037078A1 (en) 2' -disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
US9926295B2 (en) Potent and selective inhibitors of hepatitis C virus

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141215

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20141215

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20150119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150527

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150929

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151020

R150 Certificate of patent or registration of utility model

Ref document number: 5828903

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees